Insmed reported $1.71B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
DBV Technologies USD 189.6M 12.3M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Novartis USD 28.75B 2.14B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026